Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Francesca Mordant and Kanta Subbarao.
Francesca Mordant
Connection Strength
1.305
Kanta Subbarao
  1. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience. Eur J Immunol. 2020 10; 50(10):1447-1453.
    View in: PubMed
    Score: 0.226
  2. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines. J Infect Dis. 2019 04 08; 219(Suppl_1):S81-S87.
    View in: PubMed
    Score: 0.204
  3. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021 08 23; 6(16).
    View in: PubMed
    Score: 0.060
  4. Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia. Emerg Infect Dis. 2021; 27(8):2233-2235.
    View in: PubMed
    Score: 0.059
  5. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 05 11; 118(19).
    View in: PubMed
    Score: 0.059
  6. Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. Open Forum Infect Dis. 2021 Jul; 8(7):ofab239.
    View in: PubMed
    Score: 0.059
  7. Temporal differences in culturable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) from the respiratory and gastrointestinal tracts in a patient with moderate coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol. 2021 May 10; 1-3.
    View in: PubMed
    Score: 0.059
  8. Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection. Cell Rep. 2021 05 11; 35(6):109108.
    View in: PubMed
    Score: 0.059
  9. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021 10; 21(10):1383-1394.
    View in: PubMed
    Score: 0.059
  10. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin Transl Immunology. 2021; 10(4):e1269.
    View in: PubMed
    Score: 0.059
  11. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun. 2021 03 03; 12(1):1403.
    View in: PubMed
    Score: 0.058
  12. Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. Clin Transl Immunology. 2021; 10(3):e1258.
    View in: PubMed
    Score: 0.058
  13. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021 02 19; 12(1):1162.
    View in: PubMed
    Score: 0.058
  14. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. 2021 03 16; 2(3):100208.
    View in: PubMed
    Score: 0.058
  15. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat Commun. 2020 11 11; 11(1):5703.
    View in: PubMed
    Score: 0.057
  16. Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. J Infect Dis. 2020 09 14; 222(8):1280-1288.
    View in: PubMed
    Score: 0.056
  17. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020 09; 26(9):1428-1434.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.